Human CCR4 Virus-Like Particles

CCR4 (C-C chemokine receptor type 4) is a G protein-coupled receptor primarily expressed on the surface of immune cells, including Th2 lymphocytes, regulatory T cells (Tregs), and certain dendritic cells. It plays a key role in immune regulation by binding to specific chemokines, such as CCL17 (TARC) and CCL22 (MDC). These interactions promote cell migration to sites of inflammation, making CCR4 a key mediator of allergic reactions, autoimmune diseases, and cancer metastasis. Due to its involvement in various pathological conditions, CCR4 has become a promising therapeutic target. For example, monoclonal antibodies targeting CCR4 have been developed for the treatment of cancers such as adult T-cell leukemia/lymphoma (ATLL).

Human CCR4 virus-like particles (VLPs) are non-infectious nanostructures designed to mimic the native conformation of CCR4 found on viral envelopes or cell membranes. VLPs are engineered by expressing CCR4 and viral structural proteins (such as HIV-1 Gag or influenza hemagglutinin). These proteins self-assemble into particles that resemble viruses but lack genetic material, ensuring safety for both research and therapeutic applications. These particles retain the tertiary structure and post-translational modifications of CCR4, making them valuable tools for studying receptor-ligand interactions, antibody development, and vaccine design. For example, CCR4 VLPs can be used to screen for neutralizing antibodies or evaluate the immunogenicity of CCR4-targeting vaccines for cancer immunotherapy. Furthermore, their high-density CCR4 display enhances binding affinity, thereby improving the sensitivity of diagnostic assays.